Prostate-specific Antigen: Its Usefulness in Clinical Medicine

Prostate-specific antigen (PSA) was discovered about 20 years ago and over the last decade it has become the premier tumor marker for diagnosis, monitoring and prognosis of prostatic carcinoma. PSA is now considered to be the best tumor marker available in clinical medicine. It is the only tumor marker that has been approved by the Food and Drug Administration of the USA for mass screening: for the purpose of diagnosing early prostatic carcinoma. Among the newest developments in the field are the discovery of the molecular forms of PSA in serum, the development of ultrasensitive assays that allow better monitoring of patients after radical prostatectomy, and the discovery of non-prostatic PSA. Indeed, there are indications that PSA might be useful for the diagnosis and prognosis of breast cancer. The genomic structure of PSA and other human kallikrein genes and the regulation of their expression has recently been elucidated. Currently, the PSA promoter and enhancer are being investigated in connection with gene therapy in prostatic tissue. Efforts are now underway to supplement the clinical value of PSA measurements with additional prostatic markers, including human kallikrein 2 (hK2) and prostate-specific membrane antigen (PSMA).

[1]  G. Sensabaugh,et al.  Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. , 1978, Journal of forensic sciences.

[2]  T. Stamey.  Some comments on progress in the standardization of immunoassays for prostate-specific antigen. , 1997, British journal of urology.

[3]  T. Stamey,et al.  Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer. , 1997, Urology.

[4]  J. Cadeddu,et al.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. , 1998, The Journal of urology.

[5]  P. Sismondi,et al.  Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. , 1995, Cancer research.

[6]  R. Vessella,et al.  Screening for prostatic carcinoma with prostate specific antigen: results of the second year. , 1993, The Journal of urology.

[7]  J. Oesterling,et al.  Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. , 1995, Urology.

[8]  E. Diamandis,et al.  Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[9]  J. Trapman,et al.  An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. , 1997, Molecular endocrinology.

[10]  T. Deguchi,et al.  Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. , 1993, Cancer research.

[11]  D. Peehl.  Prostate specific antigen role and function , 1995 .

[12]  C. López-Otín,et al.  Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. , 1998, Endocrine reviews.

[13]  A. Tewari,et al.  The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. , 1995, Urology.

[14]  W. Ellis,et al.  Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay. , 1997, Urology.

[15]  R. Vessella,et al.  Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies. , 1997, Clinical chemistry.

[16]  L. Witherspoon,et al.  Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. , 1997, The Journal of urology.

[17]  R. Wolfert,et al.  A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. , 1997, Urology.

[18]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[19]  J. Trachtenberg,et al.  Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L. , 1997, The Journal of urology.

[20]  E. Diamandis,et al.  Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. , 1997, British Journal of Cancer.

[21]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[22]  E. Diamandis.  Prostate cancer, prostate-specific antigen, and the polymerase chain reaction. , 1995, Clinical chemistry.

[23]  E. Diamandis,et al.  Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. , 1996, Clinical chemistry.

[24]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[25]  J. Oesterling,et al.  The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. , 1993, JAMA.

[26]  R. Vessella,et al.  Improved reverse transcriptase-polymerase chain reaction protocol with exogenous internal competitive control for prostate-specific antigen mRNA in blood and bone marrow. , 1997, Clinical chemistry.

[27]  D. Armbruster,et al.  Prostate-specific antigen: biochemistry, analytical methods, and clinical application. , 1993, Clinical chemistry.

[28]  J. Cadeddu,et al.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy: Reply by authors , 1998 .

[29]  E. Diamandis.  Clinical application of ultrasensitive prostate-specific antigen assays. , 1997, Journal of the National Cancer Institute.

[30]  E. Diamandis.  Prostate-Specific Antigen or Human Kallikrein 3? , 1998, Tumor Biology.

[31]  E. Diamandis,et al.  New biological functions of prostate-specific antigen? , 1995, The Journal of clinical endocrinology and metabolism.

[32]  T. Deguchi,et al.  Micrometastasis of prostate cancer to lymph nodes: detection by means of reverse transcription-polymerase chain reaction. , 1997, Journal of the National Cancer Institute.

[33]  J. D. Miller,et al.  Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer (*) , 1996, The Journal of Biological Chemistry.

[34]  T. Stamey,et al.  A comparison of 4 ultrasensitive prostate specific antigen assays for early detection of residual cancer after radical prostatectomy. , 1994, The Journal of urology.

[35]  E. P. Diamandis,et al.  Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. , 1996, Clinical biochemistry.

[36]  E. Diamandis,et al.  Elevated levels of prostate-specific antigen in serum of women with fibroadenomas and breast cysts. , 1997, Journal of the National Cancer Institute.

[37]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[38]  T. M. Chu,et al.  Prostate-specific antigen and early detection of prostate cancer. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[39]  G. Murphy,et al.  Prostate-specific membrane antigen: current and future utility. , 1998, Seminars in urologic oncology.

[40]  L. Chung,et al.  A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. , 1997, Molecular endocrinology.

[41]  T. S. Li,et al.  Isolation and characterization of two specific antigens of human seminal plasma. , 1973, Fertility and sterility.

[42]  T. Stamey,et al.  Identity of prostate specific antigen and the semen protein P30 purified by a rapid chromatography technique. , 1990, The Journal of urology.

[43]  U. Stenman,et al.  Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. , 1995, Clinical chemistry.

[44]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[45]  A. Partin,et al.  Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. , 1998, Critical reviews in clinical laboratory sciences.

[46]  G. Murphy,et al.  Purification of a human prostate specific antigen. , 1979, Investigative urology.

[47]  M. Hara,et al.  [Some physico-chemical characteristics of " -seminoprotein", an antigenic component specific for human seminal plasma. Forensic immunological study of body fluids and secretion. VII]. , 1971, Nihon hoigaku zasshi = The Japanese journal of legal medicine.

[48]  J. Dekernion,et al.  Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen. , 1997, The Journal of urology.